PMC:7195088 / 31140-31341
Annnotations
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T34","span":{"begin":16,"end":24},"obj":"Body_part"},{"id":"T35","span":{"begin":79,"end":81},"obj":"Body_part"},{"id":"T36","span":{"begin":95,"end":97},"obj":"Body_part"}],"attributes":[{"id":"A34","pred":"fma_id","subj":"T34","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A35","pred":"fma_id","subj":"T35","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A36","pred":"fma_id","subj":"T36","obj":"http://purl.org/sig/ont/fma/fma86578"}],"text":"monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytoki"}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T173","span":{"begin":52,"end":60},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"}],"text":"monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytoki"}
LitCovid-PD-CHEBI
{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T418","span":{"begin":26,"end":37},"obj":"Chemical"},{"id":"T419","span":{"begin":79,"end":81},"obj":"Chemical"},{"id":"T421","span":{"begin":95,"end":97},"obj":"Chemical"}],"attributes":[{"id":"A418","pred":"chebi_id","subj":"T418","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A419","pred":"chebi_id","subj":"T419","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A420","pred":"chebi_id","subj":"T419","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A421","pred":"chebi_id","subj":"T421","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A422","pred":"chebi_id","subj":"T421","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"monoclonal IgG1 antibody, tocilizumab inhibits both membrane-bound and soluble IL-6 receptors. IL-6, is one of the main drivers of immunologic response and symptoms in patients with dysregulated cytoki"}